Fig 1: Increased JAG1/NOTCH signaling and angiogenesis in the prostate ICC/IDC TME.a Unsupervised graph-based clustering of all samples visualized by UMAP highlighted for endothelial clusters 0 and 22 and SMC cluster 13 delineated by benign-enriched and ICC/IDC-enriched prostate. b Violin plots of endothelial, blood, and lymphoid marker expression in clusters 0 and 22. c Violin plots of SMC and pericyte markers in clusters 13 and 20. d Violin plots of NOTCH receptor expression in clusters 0–25. e Violin plots of NOTCH-induced genes in endothelial clusters 0 and 22 and SMC cluster 13 delineated by benign-enriched and ICC/IDC-enriched prostate. f Violin plots of markers differentially enriched in cluster 0 compared to cluster 22. g Percent total of EpCAM-/CD45- benign-enriched and ICC/IDC-enriched prostate cells per endothelial cluster (0 and 22). The graph shown as mean ± SEM and analyzed by Wilcoxon matched-pair signed rank two-tailed test; n = 7 biologically independent samples. The graph is also shown as part of Fig. 2d. h PssGSEA of hallmark pathways in ICC/IDC-enriched prostate compared to benign-enriched prostate in clusters 0 and 22. i Violin plots of markers in ICC/IDC-enriched prostate compared to benign-enriched prostate in clusters 0 and 22. j UMAP visualization of cluster 13 after re-clustering. k Percent of cells in clusters 13–0 through 13–7. The graph is shown as mean ± SEM and analyzed by Wilcoxon matched-pair signed rank two-tailed test; n = 7 biologically independent samples. l Violin plots of markers in clusters 13–0 through 13–3. m Representative images of CD31 expression by IHC in ICC/IDC prostate cancer from RP (n = 7 biologically independent samples) at 100x (bar = 100 µm) and 400x. Source data are provided as a Source Data file.